Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP Jr. Cunningham C, et al. Among authors: jekunen a. Clin Cancer Res. 2005 Nov 1;11(21):7825-33. doi: 10.1158/1078-0432.CCR-05-0058. Clin Cancer Res. 2005. PMID: 16278405 Clinical Trial.
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
Kellokumpu-Lehtinen PL, Marttila T, Jekunen A, Hervonen P, Klintrup K, Kataja V, Utriainen T, Luukkaa M, Leskinen M, Pulkkanen K, Kautio AL, Huttunen T. Kellokumpu-Lehtinen PL, et al. Among authors: jekunen a. Anticancer Res. 2020 Dec;40(12):6915-6921. doi: 10.21873/anticanres.14715. Epub 2020 Dec 7. Anticancer Res. 2020. PMID: 33288585 Clinical Trial.
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
O'Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, Cvetanovic A, Wilks S, Ribeiro L, Burotto M, Klingbiel D, Messeri D, Alexandrou A, Trask P, Fredriksson J, Machackova Z, Stamatovic L; PHranceSCa study group. O'Shaughnessy J, et al. Eur J Cancer. 2021 Jul;152:223-232. doi: 10.1016/j.ejca.2021.03.047. Epub 2021 Jun 16. Eur J Cancer. 2021. PMID: 34147014 Free article. Clinical Trial.
[Hodgkin disease and amyloidosis].
Jekunen A, Maiche A, Laurila P, Franssila K, Elomaa I. Jekunen A, et al. Duodecim. 1994;110(6):602-6. Duodecim. 1994. PMID: 7555860 Finnish. No abstract available.
108 results